MedTrace Logo

Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

NCT06091995 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2026-03-27

No results posted yet for this study

Summary

Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.

Conditions

  • Use of Belatacept in Kidney Transplant Patients

Interventions

BEHAVIORAL

impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)

Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Erin Loncharic, PharmD · Methodist Health System

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-22
Primary Completion
2025-07-07
Completion
2025-07-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06091995 on ClinicalTrials.gov